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SUMMARY  
Introduction : Metformin is the first-choice drug in the management of type 2 diabetes. 
However, most patients require a combined therapy to reach and/or maintain targets of 
glucose control. Dipeptidyl peptidase-4 (DPP-4) inhibitors offer new options for combined 
therapy with metformin. Linagliptin shares a similar pharmacodynamic (PD) profile with 
other gliptins, but has a unique pharmacokinetic (PK) profile characterized by negligible renal 
excretion. 
Areas covered : An extensive literature search was performed to analyze the potential PK/PD 
interactions between linagliptin and metformin. They are not prone to PK drug-drug 
interactions. The two compounds may be administered together, either separately or using a 
fixed-dose combination (FDC) as shown by bioequivalence studies. The addition of 
linagliptin in patients not well controlled with metformin alone has proven its efficacy in 
improving glucose levels with a good safety profile. Initial co-administration of linagliptin 
plus metformin improves glucose control more potently than either compound separately, 
without hypoglycaemia, weight gain or increased metformin-related gastrointestinal side 
effects.  
Expert opinion : The linagliptin plus metformin combination may may offer some 
advantages over the classical sulfonylurea-metformin combination. Even if linagliptin is safe 
in patients with renal impairment, the use of metformin (and thus of the linagliptin plus 
metformin FDC) is still controversial in this population. 
 
 
Key-words : DPP-4 inhibitor – Fixed-dose combination – Linagliptin – Metformin  – 
Pharmacokinetics – Type 2 diabetes mellitus 
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1. Introduction  
 Even if metformin is unanimously considered as the first-line drug therapy in type 2 
diabetes (T2DM), which treatment to be added after metformin failure remains a quite 
challenging issue1, 2. Indeed, what ever the mode of action, almost all second-drug therapies offer 
quite similar efficacy regarding glycated hemoglobin (HbA1c) lowering effect1, 3.However, 
T2DM is often accompanied by other conditions and risk factors, on which the various 
glucose-lowering agents may exert different effects that may have an impact on long-term 
clinical outcomes and, thereby, may influence physician’s drug choice4, 5. Classical insulin 
secretagogues include sulfonylureas (still recommended because of their low cost),2 but these 
glucose-lowering agents expose to a risk of potentially severe hypoglycemia, weight gain and 
drug-drug interactions (DDIs), which may worsen outcomes5. In this regard, dipeptidyl 
peptidase-4 (DPP-4) inhibitors, which inhibit the inactivation of glucagon-like peptide- 1 
(GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), two gastrointestinal incretin 
hormones, may offer new opportunities in the management of T2DM6-8. Indeed, GLP-1 
stimulates insulin secretion and inhibits glucagon secretion in a glucose-dependent manner, 
which explains the minimal risk of hypoglycemia associated with such incretin-based therapies8. 
Furthermore, GLP-1 contributes to appetite regulation and thereby may avoid or at least limit 
weight gain despite improvement of glucose control in T2DM patients, in contrast to what is 
generally observed with other glucose-lowering therapies6, 9. However, the positioning of DPP-4 
inhibitors in the management of T2DM, especially their place compared with sulfonylureas after 
metformin failure10-12, is still a matter of debate. 
 Several DPP-4 inhibitors are currently available (sitagliptin, saxagliptin, vildagliptin 
except in United States, alogliptin only in Japan, more recently linagliptin)7, 8, 13. They share a 
similar mode of action (pharmacodynamics or PD, i.e. selective inhibition of DPP-4), but they 
differ by some pharmacokinetics (PK) properties14, 15. Because they have been mostly studied as 
add-on therapy to metformin10, 16, 17, most DPP-4 inhibitors are already available as fixed dose 
combination (FDC) with metformin, especially vildagliptin18, sitagliptin19, 20 and saxagliptin21. 
FDC can offer convenience, reduce the pill burden and simplify administration regimens for 
the patient, all conditions that may improve adherence to therapy22, 23.  
 Linagliptin is the newest DPP-4 inhibitor and is characterized by specific PK 
properties24-27. The most clinically relevant specificity, relative to other already available 
DPP-4 inhibitors, is that linagliptin has a minimal renal excretion and a predominant biliary 
excretion (without previous hepatic metabolism)14, 28. Thus, it may be used in patients with 
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chronic kidney disease (CKD) without dose adjustment28. This contrasts with other DPP-4 
inhibitors, for which an appropriate dose reduction is recommended according to the decrease 
of the estimated glomerular filtration rate (eGFR)29. Therefore, linagliptin may be considered 
as a valuable alternative in T2DM patients with impaired renal function in whom metformin 
may be contraindicated30, 31.  Furthermore, in T2DM patients who may receive metformin 
(because of acceptable renal function and good gastrointestinal tolerance), linagliptin may 
also be added to the biguanide to reach HbA1c targets in case of failure of monotherapy. 
Linagliptin has also proven its efficacy and safety as a triple therapy in addition to a 
metformin plus sulfonylurea combination32. Consequently, numerous patients with T2DM are 
in a position to receive both metformin and linagliptin27. Thereby, a linagliptin plus 
metformin hydrochloride FDC (Jentadueto®) appears attractive for clinical use (see drug 
summary box).  
 The present paper provides a PK/PD evaluation of linagliptin plus metformin and an 
updated review of the randomized clinical trials and of the bioequivalence studies that have 
assessed both the efficacy and tolerability/safety of this linagliptin-metformin combination. 
We will particularly focus our analysis on the safety profile of the combination and what 
might be its potential use in patients with mild to moderate CKD and in elderly subjects 
despite the classical limitations of use of metformin in such clinical conditions. To identify 
relevant studies, an extensive literature search of MEDLINE was performed from January 
2008 to December 2012, with the two key-words “metformin” and “linagliptin”. No language 
restrictions were imposed. Reference lists of original studies, narrative reviews, previous 
systematic reviews, the European Public Assessment Report (EPAR) of the Committee for 
Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of 
the linagliptin plus metformin FDC33  and the approval document of this FDC by the Food 
and Drug Administration (FDA)34 have been also carefully examined. 
 
2. Mechanism of action of linagliptin plus metformin 
  
 2.1. Pharmacokinetic evaluation  
  
  The individual PK characteristics of metformin35, 36 and  linagliptin24, 37 have been 
reviewed elsewhere. Metformin is mainly excreted by the kidneys whereas linagliptin has a 
negligible renal excretion. This part of the present review will focus on the PK interactions 
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between linagliptin and metformin38. Only limited DDIs have been described with metformin 
and with linagliptin both in healthy volunteers and in T2DM patients35, 39, 40. Metformin is a 
substrate for organic cation transporter 1 (OCT1) and OCT236 and linagliptin showed inhibitory 
potency to OCT1 and OCT241. However, considering the low therapeutic plasma 
concentration of linagliptin, available in vitro data clearly suggest a very low risk for 
transporter-mediated DDIs on comedications, including metformin, in clinical practice41.  
 The potential PK/PD interactions between linagliptin and metformin were investigated 
in a randomised, two-way crossover design study  in 16 healthy male subjects42. Linagliptin 
(10 mg/day) and metformin (850 mg three times daily) were each administered alone and 
concomitantly (3-9 days to steady-state). Co-administration of linagliptin had no apparent 
effect on metformin exposure (area under the plasma concentration-time curve or AUC), with 
no significant changes in metformin AUC τ,ss or Cmax,ss. While co-administration of metformin 
did not significantly affect Cmax,ss of linagliptin, it slightly increased linagliptin AUC τ,ss by 
20% (Table 1). Metformin alone had no effect on DPP-4 activity, and the inhibition of DPP-4 
caused by linagliptin was not affected by concomitant administration of metformin. Thus, in 
this study, co-administration of linagliptin with metformin did not have a clinically relevant 
effect on the PK or PD of either agent42. 
Three bioequivalence studies with a similar design (open-label, randomized, single 
dose, two-way crossover, trials, in 94-96 healthy volunteers each) were performed with three 
different linagliptin/metformin FDC tablet strengths (2.5 mg/500 mg, 2.5 mg/850 mg, and 2.5 
mg/1000 mg). The results regarding AUC and Cmax demonstrated that linagliptin/metformin 
hydrochloride FDC tablets are bioequivalent to coadministration of corresponding doses of 
linagliptin and metformin as individual tablets (Table 2)33.  
Food may influence the bioavailability of metformin, linagliptin or 
linagliptin/metformin FDC (Table 3). Even if the bioavailability of metformin is slightly 
reduced by food43, 44, it is generally recommended to take metformin with a meal in order to 
improve gastrointestinal tolerance. Intake of a high-fat meal reduced the rate of linagliptin 
absorption (increase of Tmax by about 2 hours), but had no influence on the extent of 
absorption45. These findings suggest that linagliptin can be given together with metformin 
during a meal. The effect of food on bioavailability of linagliptin/metformin FDC was 
evaluated with the higher strength of metformin. Administration of linagliptin 2.5 
mg/metformin hydrochloride 1000 mg FDC with a fat meal resulted in no change in overall 
exposure of linagliptin. There was no change in metformin AUC; however, mean peak serum 
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concentration of metformin was decreased by 18% when administered with food, confirming 
previous observations when metformin was tested alone43, 44. Furthermore, a delayed time-to-
peak serum concentrations by 2 hours was observed for metformin under fed conditions. 
These changes are not likely to be clinically significant33. 
2.2. Pharmacodynamic evaluation  
The two antidiabetic agents exert their glucose-lowering effects via different 
mechanisms, metformin essentially independently of insulin secretion whereas linagliptin 
primarily (although not exclusively) via its incretin action on insulin secretion38, 46. The 
antihyperglycemic effect of metformin is already marked in the fasting state, by inhibiting 
overnight gluconeogenesis47 whereas the DPP-4 inhibitor generally exerts a greater glucose-
lowering effect in the postprandial state than after an overnight fast48.   
The mechanism of action of metformin mainly involves suppression of hepatic 
glucose output and modestly reduction of insulin resistance49, 50. The inhibition of hepatic 
glucose production occurs mostly through a mild and transient inhibition of the 
mitochondrial respiratory chain complex I. The resulting decrease in hepatic energy status 
activates AMPK (AMP-activated protein kinase), a cellular metabolic sensor, providing a 
generally accepted mechanism for the action of metformin on hepatic gluconeogenesis51.   
Linagliptin effectively inhibited plasma DPP-4 activity in patients with T2DM, 
producing immediate improvements in incretin levels (both GLP-1 and GIP), glucagon 
suppression, and better glycemic control52, 53. The improvement in glycemic control was 
associated with enhancement of markers of B-cell function, such as proinsulin/insulin ratio, 
Homeostasis Model Assessment (HOMA)-%B, and disposition index, mostly attributed to a 
GLP-1 effect48. 
Interestingly, almost 10 years ago already, metformin was shown to increase GLP-1 
release in obese patients without or with T2DM54, 55. A more recent study confirmed that 
metformin monotherapy in obese patients with T2DM was associated with increased postprandial 
GLP-1 levels, including its active form, over a 6-h period following a standard mixed meal, 
without changes in DPP-4 activity56. These data confirmed that metformin-induced increase in GLP-
1 levels is independent of DPP-4 inhibition after a meal44, 57. The mechanisms of action 
explaining why metformin may promote GLP-1 secretion from L cells are rather complex58, 
59.  Recent experimental studies in rats suggested that metformin enhances circulating levels 
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of GLP-1 through a peripheral muscarinic (M3) and gastrin-releasing peptide (GRP) 
receptor-dependent mechanism58. It has also been shown that metformin protects against 
lipoapoptosis (possibly by blocking JNK2 activation), and enhances GLP-1 secretion from GLP-1-
producing cells in vitro59.  Finally, in a recent study in T2DM patients, whose results contrast 
with some previous observations42, 56, the use of metformin was associated with a significantly 
lower DPP-4 activity, independently of age, sex, body mass index and HbA1c60. All together, the 
combination of a DPP-4 inhibitor and metformin led to greater increases in active GLP-1 
than either treatment alone57, which may represent a further argument in favor of this 
combination and the commercialization of a gliptin-metformin FDC61.  
 
3. Clinical applications 
3.1. Addition of linagliptin to metformin monotherapy (Table 4) 
All clinical trials having tested the addition of linagliptin to metformin were performed 
in T2DM patients not well controlled (HbA1c 6.5-7% to 10-11%) with a dose of metformin 
≥1500 mg/day or maximally tolerated dose. The follow up was rather short (12-24 weeks in 
placebo-controlled studies), except in one trial comparing linagliptin with glimepiride (104 
weeks). 
3.1.1. Comparison versus placebo  
The efficacy and safety of linagliptin, added to ongoing metformin therapy, were 
assessed in 333 patients with T2DM who had inadequate glycemic control with metformin 
alone62. Patients were randomized to receive double-blind linagliptin (1, 5 or 10 mg once 
daily) or placebo or open-label glimepiride (1-3 mg once daily). Twelve weeks of treatment 
resulted in a mean placebo-corrected lowering in HbA1c levels of -0.73% for 5 mg and -
0.67% for 10 mg, compared with -0.90% for glimepiride. There were no hypoglycemic events 
for linagliptin or placebo, whereas three patients (5%) receiving glimepiride experienced 
hypoglycemia.  
The addition of linagliptin 5 mg once daily (n=524) to metformin in T2DM patients 
with inadequate glycemic control (mean baseline HbA1c of 8.1 % and mean fasting plasma 
glucose (FPG) of 9.4 mmol/l) showed significant reductions vs. placebo (n=177) in adjusted 
mean changes (24 weeks versus baseline) of HbA1c (-0.49 vs. 0.15%), FPG (-0.59 vs. 0.58 
Page 8 
mmol/l) and 2h postprandial glucose (-2.7 vs. 1.0 mmol/l)63. Rescue glycemic therapy was 
less used in patients treated with linagliptin 5 mg than in those receiving placebo (7.8% 
vs.18.9%) and no increased risk of hypoglycemia was observed.  
As metformin is administered twice daily, a FDC of these compounds would require 
twice-daily administration of linagliptin. Therefore, a study evaluated whether 2.5 mg twice-
daily dosing of linagliptin has comparable efficacy and safety to 5 mg once-daily dosing when 
given in addition to metformin twice daily in patients with inadequate glycemic control64. A 
total of 491 T2DM patients were randomized to double-blind treatment with linagliptin 
2.5 mg twice daily, 5 mg once daily or placebo, respectively, in addition to continuing 
metformin twice daily. After 12 weeks, linagliptin 2.5 mg twice daily and 5 mg once daily 
both significantly reduced HbA1c [placebo-adjusted changes from baseline (mean level : 
7.97%)  -0.74% (95% CI -0.97, -0.52) and -0.80% (95% CI -1.02, -0.58), respectively, both 
p < 0.0001]. The treatment difference (twice daily - once daily) between the linagliptin 
regimens was 0.06 (95% CI -0.07, 0.19), the upper bound of which was less than the 
predefined noninferiority margin (0.35%). Hypoglycemia was rare and similar to placebo, 
with no severe episodes.  
3.1.2. Comparison versus a sulfonylurea 
In a 2-year double-blind trial, T2DM patients on stable metformin alone or with one 
additional oral antidiabetic drug (washed out during screening) were randomly assigned to 
linagliptin (5 mg; n=777) or glimepiride (1-4 mg; n=775) orally once daily in addition to 
metformin (daily dose ≥ 1500 mg in 93% of patients)65. Reductions in adjusted mean HbA1c 
from baseline (7.69% in both groups) to week 104 were similar in the linagliptin (-0.16%) 
and glimepiride groups (-0.36%; difference 0.20%, 97.5% CI 0.09-0.30), meeting the 
predefined non-inferiority criterion of 0.35%. Fewer participants had hypoglycemia or 
severe hypoglycemia with linagliptin compared with glimepiride (see below : 4.3). 
3.2. Initial linagliptin-metformin combined therapy 
 A potential benefit of early combined therapy in the management of T2DM may be 
explained by the complex pathophysiology of the disease and the numerous organ defects that 
may be targeted by various pharmacological interventions66. Because of the complementary 
mode of action between metformin and a DPP-4 inhibitor, it may sound clinically appealing 
to initiate a gliptin-metformin combination38, 61. 
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The efficacy and safety of initial combination therapy with linagliptin plus metformin 
versus linagliptin or metformin monotherapy in patients with T2DM were evaluated in a large 
(n=791) 24-week, double-blind, placebo-controlled, Phase III trial67. Two free combination 
therapy arms received linagliptin 2.5 mg twice daily + either low (500 mg) or high (1000 mg) 
dose metformin twice daily. Four monotherapy arms received linagliptin 5 mg once daily, 
metformin 500 mg or 1000 mg twice daily or placebo. Patients with HbA1c ≥11.0% were not 
eligible for randomization and received open-label linagliptin + high-dose metformin. The 
placebo-corrected mean change in HbA1c was superior with the two initial combined 
therapies compared to either monotherapy or placebo (Table 5). In the open-label arm, the 
mean change in HbA1c from baseline (11.8%) was -3.7%68. Hypoglycemia occurred at a 
similar low rate with linagliptin+metformin as with metformin alone.  
4. Safety evaluation  
 The safety profiles of each separate glucose-lowering agent, the biguanide compound 
metformin4, 49, 50 or the DPP-4 inhibitor linagliptin24, 69, 70, are well documented. The most 
commonly reported adverse effects associated with metformin therapy are gastrointestinal, 
and include abdominal pain, diarrhea, nausea, and anorexia. Generally these digestive adverse 
events may be minimized by initiating a low dose of metformin, gradually uptitrating the 
metformin dose, and administering the medication with meals. Using this approach, digestive 
symptoms occurred in around 10 % of the patients receiving metformin as monotherapy in the 
US multicenter metformin study, and diarrhea and nausea were characterized as severe in 
only 8% and 4% of patients, respectively71. The most critical adverse event related to 
metformin therapy is lactic acidosis, but it is a rare complication provided that contra-
indications of metformin use are respected, including CKD (see below)72. 
The safety profile of linagliptin has been analyzed in detail in previous dedicated 
reviews24, 69, 70  and is generally good and quite similar to that previously reported with other 
DPP-4 inhibitors (i.e. almost comparable to that of placebo)8, 73, 74. The long-term (52 weeks) 
safety and tolerability of oral linagliptin at either 5 or 10 mg were recently confirmed in an 
extension study of a phase III trial with T2DM Japanese patients with T2DM75. Overall the 
safety/tolerance profile of linagliptin-metformin coadministration is similar to that of 
metformin alone (Table 5).  
4.1. General tolerance profile 
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The safety of concomitantly administered linagliptin (daily dose 5 mg) and metformin 
(mean daily dose of approximately 1800 mg) has been evaluated in 2816 patients with T2DM 
treated for ≥12 weeks in clinical trials. Three placebo-controlled studies with linagliptin + 
metformin were conducted : 2 studies were 24 weeks in duration, 1 study was 12 weeks in 
duration. In the 3 placebo-controlled clinical studies, adverse events which occurred in ≥5% 
of patients receiving linagliptin + metformin (n=875) and were more common than in patients 
given placebo + metformin (n=539) included nasopharyngitis (5.7% vs 4.3%)33. In a 24-week 
factorial design study, adverse events reported in ≥5% of patients receiving linagliptin + 
metformin were more common than in patients given placebo (nasopharyngitis : 6.3 vs. 1.4%; 
diarrhea : 6.3 vs. 2.8%) and only slightly higher than with either monotherapy67. Of note, 
because of the physiological (instead of supraphysiological or pharmacological) levels of 
GLP-1 reached with the DPP-4 inhibitor, the addition of linagliptin to metformin therapy does 
not appear to cause a greater incidence of gastrointestinal side effects than does metformin 
alone. 
  4.2. Effects on body weight  
Overall, no clinically relevant changes in body weight were observed with linagliptin 
added to metformin, contrasting with the weight gain commonly observed with other glucose-
lowering agents6.  In a pooled analysis of 24-week phase III trials followed by a 78-week 
open-label extension, treatment with linagliptin was not associated with a clinically relevant 
change in body weight (-0.03 kg change in subjects previously treated with linagliptin during 
the initial 24-week period, 0.47 kg in those switched from placebo)76. In a recent two-year 
head-to-head comparative trial in T2DM patients treated with metformin, body weight 
decreased with linagliptin (−1.4 kg) but increased with glimepiride (+1.3 kg) from similar 
mean baseline values; the treatment difference was −2.7 kg (97.5% CI −3.2 to −2.2, 
p<0.0001). 
 
4.3. Effects on hypoglycemia 
As already mentioned, the likelihood of treatment-related hypoglycemia is very low 
with the dual metformin plus linagliptin comnibation. This is explained by the absence of 
insulin-secreting effect of metformin (in contrast metformin is commonly associated with an 
insulin-sparing effect)49, 50 and by the glucose-dependent potentiation of insulin secretion of 
linagliptin (a property shared by all DPP-4 inhibitors leading to increased GLP-1 levels)77. 
The risk of hypoglycemia only increased when linagliptin or linaglipin-metformin are 
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coprescribed with a sulfonylurea76. In a large (n=1058 T2DM patients) multi-centre, 24-week, 
randomized, double-blind, parallel-group study comparing linagliptin (5 mg once daily) and 
placebo when added to metformin plus sulfonylurea, symptomatic hypoglycemia occurred in 
16.7 and 10.3% of the linagliptin and placebo groups, respectively78. Hypoglycemia was 
generally mild or moderate and no more severe hypoglycemia was reported with linagliptin 
than with placebo. In a 2-year head-to-head trial comparing linagliptin 5 mg or glimepiride 1-
4 mg orally once daily in patients with T2DM insufficiently controlled with metformin, fewer 
participants had hypoglycaemia (7% vs 36%, p<0·0001) or severe hypoglycaemia (1 episode 
vs. 12 episodes) with linagliptin compared with glimepiride65. 
 
4.4. Effects on pancreatitis and pancreatic cancer 
Because patients with T2DM exhibit significantly increased rates of acute pancreatitis, 
large case control studies are required to ascertain whether a specific antidiabetic therapy 
independently modifies the risk of developing pancreatitis79. DPP-4 inhibitors, by increasing 
GLP-1 levels, were suspected to be associated with an increased risk of pancreatitis and even 
pancreatic cancer80. In a controversial paper that examined the US FDA database of reported 
adverse events, the use of sitagliptin was shown to increase the odds ratio for reported 
pancreatitis 6-fold (an increase almost similar to that noticed for the GLP-1 receptor agonist 
exenatide)  as compared with other glucose-lowering therapies81. However, reporting bias 
may be suspected to explain these observations. In a general review on the tolerability of 
DPP-4 inhibitors, pancreatitis was reported at lower rates with gliptins compared with other 
oral antihyperglycemic agents73. In the large database on linagliptin, no case of acute 
pancreatitis (1 chronic pancreatitis among 2523 patients) and no case of pancreatic cancer 
have been described69. The conclusion of a recent review was that the available data set from 
multiple independent sources does not currently support a mechanistic or epidemiological link 
between incretin therapies and the development of acute pancreatitis; however, longer studies 
with greater numbers of patients are needed for more robust conclusions to be drawn79.  
Indeed, various experimental data in animal models suggested that there are grounds 
for concern that the GLP-1 class of drugs may induce asymptomatic pancreatitis and, perhaps 
over time in some individuals, induce pancreatic cancer80. Of potential interest, pancreatic 
ductal proliferation induced by GLP-1 could be prevented by coadministration of metformin 
in a rat model82. Whether such protection may also be expected in humans remains to be 
demonstrated, even if some experimental and clinical data have already suggested that 




4.5. Effects on cardiovascular events 
 
T2DM is associated with a higher risk of CV events and some glucose-lowering 
agents may be associated with an increased rather a decreased risk of CV events. Therefore, 
especially since the rosiglitazone story, the FDA now requests that new glucose-lowering 
agents demonstrate CV safety84. Metformin may be associated with a lower incidence of CV 
events when the drug is used as monotherapy85. However, the level of evidence of the CV 
protection of metformin has been challenged recently, perhaps partially because of the 
pollution by the coprescription with sulfonylureas86.  
Post-hoc analyses of phase II-III trials with DPP-4 inhibitors showed that this incretin-
based class of pharmacological compounds may be associated with a reduced incidence of CV 
events87. In a a pre-specified, prospective and adjudicated meta-analysis of CV events in 
linagliptin or comparator-treated patients with T2DM from eight Phase 3 studies, primary CV 
events occurred in 11 (0.3%) patients receiving linagliptin and 23 (1.2%) receiving 
comparators; the hazard ratio (HR) for the primary endpoint showed significantly lower risk 
with linagliptin than comparators (HR 0.34; 95% CI 0.16-0.70). These preliminary results 
support the hypothesis that linagliptin may have CV benefits in patients with T2DM88.  
Whether the combination of linagliptin (or another DPP-4 inhibitor) and metformin would 
result in a significant reduction of the incidence of CV events in T2DM patients at high CV 
risk remains to be demonstrated. Of potential interest, recent data from a 104-week trial 
showed a lower incidence of CV events with linagliptin added to metformin compared with 
the addition of a sulfonylurea (glimepiride) to metformin (12 vs. 26 patients; relative risk 
0.46, 95% CI 0.23-0.91, p=0.0213)65. This finding was mainly attributable to a significantly 
lower number of non-fatal strokes in patients on linagliptin compared with glimepiride (RR 
0.27, 95% CI 0.08–0.97; p=0.0315) rather than to a reduction in mortality or acute coronary 
infarctions. Further information on the CV safety and efficacy of linagliptin versus 
glimepiride will be provided by the ongoing prospective CAROLINA (“CARdiovascular 
Outcome study of LINAagliptin versus glimepiride in patients with T2DM”) study in which 
most probably numerous patients will receive metformin as baseline therapy89. The results of 
this trial are waited with interest because of the controversy concerning the CV safety of the 




4.6. Safety concern in patients with CKD 
 
Because patients with T2DM are better protected against CV disease and thereby live 
longer, more and more patients are exposed to the development of CKD90. Thus, the efficacy 
and more especially the safety of a gliptin plus metformin combination in patients with CKD 
deserve much attention91.   
 
4.6.1. Linagliptin in patients with CKD 
The influence of various degrees of renal impairment on the exposure of linagliptin 
was assessed in subjects with and without T2DM28. Linagliptin PK (5 mg once daily) was 
studied under single-dose and steady-state conditions (administration for 7-10 days) in 
subjects with mild (creatinine clearance > 50 to < 80 ml/min), moderate (> 30 to < 50 
ml/min), and severe (< 30 ml/min) CKD and end-stage renal disease (< 30 ml/min on 
hemodialysis), and compared with the PK in subjects with normal renal function. Renal 
excretion of unchanged linagliptin was <7% in all groups. Although there was a tendency 
towards slightly higher (20-60%) exposure in subjects with CKD compared with subjects with 
normal renal function, the steady-state AUC and Cmax values showed a large overlap and were 
not affected by the degree of renal impairment (in contrast to what was observed  with other 
DPP-4 inhibitors). Thus, CKD has a minor effect on linagliptin PK, a finding that has been 
confirmed in post-hoc analyses of the trough plasma levels of linagliptin in the global Phase 
III program investigating linagliptin 5 mg once daily for 24-52 weeks in patients with T2DM 
and various degress of renal impairment24.  
 
Another pooled analysis of 3 randomized, placebo-controlled, Phase 3 clinical trials 
evaluated the effect of renal function on the efficacy and safety of linagliptin. Data were 
available for 2141 patients with T2DM who were grouped by renal function as normal (GFR 
≥80 mL/min, n=1684), mild CKD (GFR, 50 to <80 mL/min, n=418), or moderate CKD (GFR, 
30 to <50 mL/min, n=39). Linagliptin showed consistent placebo-corrected adjusted mean 
HbA1c changes after 24 weeks across all 3 groups: normal renal function (-0.63%), mild CKD 
(-0.69%), and moderate CKD (-0.69%), with no significant inter-group difference. Linagliptin 
was generally well tolerated, with an incidence rate of serious adverse events with linagliptin 
similar to placebo92. 
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Finally, a recent randomized, double-blind, placebo-controlled Phase 3 trial evaluated 
the efficacy and safety of linagliptin in patients with T2DM and severe CKD (GFR <30 
mL/min/1.73 m2; average level at inclusion : 23.5±6.7 mL/min/1.73 m2)93. Patients were 
treated with either linagliptin 5 mg once daily (n=68) or placebo (n=65); antidiabetic 
background therapy remained unchanged. Linagliptin induced significantly greater HbA1c 
reductions at week 12 compared to baseline in the full analysis set (-0.8% versus -0.2% with 
placebo) and in the subgroup of poorly controlled patients (baseline HbA1c ≥9%) (-1.5% vs. -
0.3%). Hypoglycemia occurred more frequently in linagliptin-treated patients than in placebo-
treated patients, an observation that may be explained by unchanged doses of insulin and/or 
sulfonylurea background therapy. Other adverse event rates were similar for linagliptin and 
placebo.  
 Because metformin is classically contraindicated in patients with renal impairment, 
GFR < 60/min was considered an exclusion criterion in all these trials and thereby the 
linagliptin plus metformin combination has not been evaluated in patients with moderate to 
severe CKD.  
 
4.6.2. Metformin in patients with CKD 
 
The use of metformin is classically contraindicated in patients with CKD, as stated in 
the labeling of the drug. However, the biological criteria used to define CKD may vary 
between countries. Today’s U.S. Food and Drug Administration prescribing guidelines for 
metformin contraindicate its use in men and women with serum creatinine concentrations  ≥ 
1.5 and  ≥ 1.4 mg/dL (≥ 132 and ≥ 123 mmol/L), respectively. According to the EU label, 
metformin is contraindicated in patients with a creatinine clearance < 60 ml/min and this 
parameter should be determined before initiating treatment and regularly thereafter. There is 
an ongoing debate, however, as to whether these thresholds are too restrictive and that those 
T2DM patients with mild–moderate renal impairment would gain more benefit than harm 
from using metformin.30 As an example, in patients having T2DM with established 
atherothrombosis participating in the Reduction of Atherothrombosis for Continued Health 
(REACH) Registry, the 2-year mortality rate associated with metformin vs. other glucose-
lowering agents was significantly lower in patients with an estimated creatinine clearance of 
30 to 60 mL/min/1.73 m² (adjusted hazard ratio 0.64; 95% CI, 0.48-0.86; P=0.003)94. In the 
UK, the National Institute for Health and Clinical Excellence (NICE) guidelines are less 
proscriptive and more evidence-based than those in the USA, generally allowing use of 
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metformin down to a GFR of 30 ml/min, with dose reduction advised at 45 ml/min.95 Given 
the current widespread reporting of estimated GFR and the available evidence of  the safety 
profile of metformin in patients with mild-moderate CKD30, these guidelines appear very 
reasonable as stated in the recent ADA-EASD position statement2. If this extension of use of 
metformin is accepted in the future, this will result in an extension of the opportunities of 
prescribing a linagliptin plus metformin combination in patients with T2DM.  
  
 
 4.7. Safety concern in the elderly T2DM patients 
 
 Because of their overall safety profile, especially the negligible risk of hypoglycemia, 
DDP-4 inhibitors are attractive for the management of elderly patients with T2DM96, 97. A 
large cohort study of elderly (> 65 years) patients with T2DM uncontrolled on metformin 
alone showed that the incidence of hypoglycemia was three times higher in patients 
prescribed a conventional oral antidiabetic drug (a sulfonylurea in most instances) versus a 
DPP4 inhibitor after 6 months (incidence of hypoglycemia/severe hypoglycemia : 
20.1%/2.4% versus 6.4%/0.1%; P<0.001) while both treatments induced satisfactory glycemic 
control98. No study was published regarding the use of linagliptin in the elderly population97, 
but a specific trial in this population is ongoing99. In the large database from eight 
randomized, double-blind, placebo-controlled Phase III clinical trials lasting ≥ 24 weeks, 
21.2% among 2523 patients were aged between 65 and 75 years and only 3.1% were ≥ 75 
years69. 
  
During many years, metformin has been contraindicated in elderly patients because a 
higher risk of lactic acidosis72. However, in T2DM patients of the REACH Registry, the 2-
year mortality rate associated with metformin vs. other glucose-lowering agents was 
significantly lower in patients older than 65 years (adjusted HR : 0.77; 0.62-0.95; P = 0.02), 
as it was in younger individuals. Mortality was also decreased among metformin users older 
than 80 years but not significantly (HR, 0.92; 95% CI, 0.66-1.28)94. A recent study in Poland  
indicated a relatively good tolerability of metformin by elderly patients (mean age 67 years) 
with the traditional contraindications to this drug100. These findings support the suggestion 




5. Linagliptin plus metformin FDC  
The linagliptin plus metformin FDC has been developed as tablets with three different 
dosage forms and strengths to be administered twice daily : linagliptin 2.5 mg plus metformin 
hydrochloride 500 mg, linagliptin 2.5 mg plus metformin hydrochloride 850 mg and 
linagliptin 2.5 mg plus metformin hydrochloride 1000 mg. This FDC may be prescribed when 
treatment with both linagliptin and metformin are appropriate. The dosage should be 
individualized on the basis of both effectiveness and tolerability, while not exceeding the 
maximum recommended dose of 2.5 mg linagliptin/1000 mg metformin hydrochloride twice 
daily. Dose escalation should be gradual to reduce the gastrointestinal side effects associated 
with metformin use. Because of the presence of metformin, the FDC is not recommended in 
hepatic impairment or hypoxic states and is contraindicated in renal impairment, although 
such later restriction might be dampened in a near future provided that patient’s careful 
supervision of renal function is warranted.  
Linagliptin plus metformin combination, given separately, has proven its superiority as 
compared to either monotherapy, with a good safety profile67. However, there is no study 
having evaluated the long-term effect of the FDC linagliptin plus metformin so far. 
6. Conclusion 
 The combination of metformin, the first choice glucose-lowering drug, and a DPP-4 
inhibitor such as linagliptin sounds as a valuable option in the management of patients with 
T2DM. Indeed, the two compounds act via different, albeit complementary, mechanisms 
leading to an additive glucose-lowering activity. Together, the two compounds tackle various 
main defects in the pathophysiology of T2DM, i.e. impaired insulin secretion, increased 
glucagon levels, increased hepatic glucose production and decreased insulin sensitivity, 
resulting in significant reductions in both fasting and posprandial glucose plasma 
concentrations. Statistically significant and clinically relevant reductions in HbA1c levels 
have been described when linagliptin 5 mg was added in patients not reaching individually 
selected HbA1c targets with metformin alone or even with  metformin plus sulfonylurea 
therapy. There are no clinically relevant PK DDIs between linagliptin and metformin reported 
so far and no major influence of food on PK of either compound has been described. 
Linagliptin 2.5 mg twice daily had non-inferior HbA1c-lowering effects compared to 5 mg 
once daily, with comparable safety and tolerability, in T2DM patients inadequately controlled 
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with metformin. These observations open the door to the launch of a linagliptin plus 
metformin FDC to be given twice daily with a meal. 
Overall, the safety profile of linagliptin is comparable to that of placebo, even when 
the DPP-4 inhibitor is combined with metformin; in particular, there is no worsening of the 
well known gastrointestinal side effects of the biguanide present in some patients. No special 
adverse effects have been reported, especially no weight gain and no severe hypoglycemia, so 
that this combination may be used safely in a large proportion of patients with T2DM, 
including elderly people, even if some concern remains in presence of CKD.   
Linagliptin may be used in T2DM patients with any degree of renal impairment, 
because of its negligible renal excretion, a characteristic that differentates this compound from 
other DPP-4 inhibitors. In contrast, caution is recommended with metformin use in patients 
with CKD because of the risk of drug accumulation and lactic acidosis, a rare but potentially 
fatal complication. Thus, linagliptin plus metformin, either separately or as FDC, can only be 
prescribed when treatment with both pharmacological agents is appropriate. Recent 
observations suggest that metformin may be used in patients with mild to moderate CKD 
under strict medical supervision. Further studies are expected to prove the long-term benefit 
of the linagliptin plus metformin combination, especially with the demonstration of a reduced 
incidence of vascular complications as currently investigated in the prospective trial 
CAROLINA.  
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Table 1 : Pharmacokinetics interactions between linagliptin (10 mg/day) and metformin (850 mg three times daily) in healthy volunteers. Results are expressed 
as geometric mean ratio [GMR] co-administration:individual administration (90% confidence interval)42.  AUC(tau,ss) : area under the concentration-time curve 
at steady state. C(max,ss) : maximum observed concentration during a dosing interval. 
 
Effect of linagliptin on metformin exposure  






Effect of metformin on linagliptin exposure 








Table 2 : Results from open-label, randomised, single dose, two-way crossover, trials studying the bioequivalence between fixed-dose combinations (FDC) and 
separate tablets (reference) of linagliptin (2.5 mg) and three different strengths of metformin hydrochloride (1000 mg  500 mg and 850 mg) in 94-96 healthy 
volunteers. Results are expressed as geometric mean ratio [GMR] FDC : reference with separate tablets (90% confidence interval). Adapted from reference33. 
 
Treatment 
LINA/MET 2.5 mg/1000 mg FDC 
vs.  
LINA 2.5 mg + MET 1000 mg 
LINA/MET 2.5 mg/500 mg FDC 
vs.  
LINA 2.5 mg + MET 500 mg 
LINA/MET 2.5 mg/850 mg FDC 
vs.  




























































LINA = linagliptin. MET = metformin. FDC : fixed-dose combination. AUC0-72 : area under the plasma concentration-time curve from time zero to 72 hours. 
AUC0-Z : area under the plasma concentration-time curve from time zero to last timepoint with a plasma concentration above the quantification limit. Cmax : 
maximum plasma concentration. 
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Table 3 : Effects of food (high-fat meal) on the bioavailability of metformin and linagliptin. Results are expressed as geometric mean ratio [GMR] fed:fasted 
state (90% confidence interval). AUC ; Area under the concentration-time curve. Cmax : maximum measured plasma concentration. NA : not available.  
Effect of food on metformin exposure 
(metformin tablet 850 mg; 24 healthy volunteers)43 
Changes in plasma levels 
AUC  Cmax 
- 24 % 
(NA) 
- 39 % 
(NA) 
Effect of food on metformin exposure 






Effect of food on linagliptin exposure 
(linagliptin tablet 5 mg; 32 healthy volunteers)45 
GMR (fed/fasted state) 





Effect of food on metformin exposure 
(linagliptin 2.5 mg + metformin hydrochloride 
1000 mg FDC; 32 healthy volunteers)33  






Effect of food on linagliptin exposure 
(linagliptin 2.5 mg + metformin hydrochloride 
1000 mg FDC; 32 healthy volunteers)33  










Table 4 : Main randomized controlled trials assessing the efficacy of adding linagliptin versus placebo or glimepiride in patients with T2DM not well controlled 





























Forst et al 201062 
Linagliptin  5 mg od 66 12 8.50/69.4 -0.48 -1.22 -0.57 0 
Linagliptin 10 mg od 66 12 8.40/68.3 -0.42 -0.90 -1.27 0 
Placebo od 71 12 8.40/68.3 +0.25 +0.70 -0.84 0 
Taskinen et al 201163 Linagliptin 5 mg od 523 24 8.09/64.9 -0.49 -0.60 -0.50 0.6 
Placebo od 177 24 8.02/64.2 +0.15 +0.60 -0.40 2.8 
Ross et al 201264 
Linagliptin  5 mg od 224 12 7.98/63.7 -0.52 -0.99* -1.0 0.9 
Linagliptin 2.5 mg bid 223 12 7.96/63.5 -0.46 -0.76* -0.4 3.1 
Placebo 44 12 7.92/63.1 +0.28 - -1.1 2.3 
Forst et al 201062 Linagliptin 5 mg od 66 12 8.50/69.4 -0.48 -1.22 -0.57 0 
Glimepiride 1-3 mg od 65 12 8.20/66.1 -0.68 NA +0.73 4.6 
Gallwitz et al 201265 Linagliptin 5 mg od 776 104 7.70/60.7 -0.16 -0.13 -1.4 7 
Glimepiride 1-4 mg od 775 104 7.70/60.7 -0.36 -0.48 +1.3 36 ** 
 
FPG : fasting plasma glucose. NA : not available. Od : once daily. Bid : twice daily. *Adjusted mean difference from placebo instead of change versus 
baseline. ** Severe hypoglycemia : 12 (2%) with glimepiride versus 1 (<1%) with linagliptin 
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Table 5 : Efficacy of the initial linagliptin-metformin combination therapy versus either monotherapy or placebo  in patients with T2DM treated with diet alone 





























Linagliptin 5mg od 135 8.70/71.6 -0.50 -0.50 +0.2 0 12.0 
Metformin 500mg bid 141 8.70/71.6 -0.60 -0.90 -0.7 1.4 9.7 
Metformin 1000 mg bid 138 8.50/69.4 -1.10 -1.80 -0.5 3.4 15.6 
Linagliptin 2.5 mg +     
Metformin 500 bid 
137 8.70/71.6 -0.20 -1.80 -0.1 
3.5 14.0 
Linagliptin 2.5 mg +  
Metformin 1000 mg bid 
140 8.70/71.6 -1.60 -2.70 -0.8 
0 19.6 
Placebo 65 8.70/71.6 +0.10 +0.60 -0.7 1.4 13.9 
Linagliptin 2.5 mg +  
Metformin 1000 mg bid*** 
66 11.80 -3.70 -4.10 NA 
1.5 19.7 
 
FPG : fasting plasma glucose. od : once daily. bid : twice daily. NA : not available * Investigator-reported  hypoglycemic events. ** GI adverse events : 
gastrointestinal adverse events (constipation, diarrhoea, gastritis, hyperchlorhydria, nausea, vomiting). *** Open-label arm in patients with HbA1c ≥11.0% not 
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Drug summary box 
 
Drug name (generic) Linagliptin plus metformin (Jentadueto®) 
Phase Approval by FDA and EMA 
Indication 1) as an adjunct to diet and exercise to improve glycemic control in adult 
patients inadequately controlled on their maximal tolerated dose of metformin 
alone; 2)  in those already being treated with the combination of linagliptin and 
metformin; and  3) in combination with a sulfonylurea (i.e. triple combination 
therapy) as an adjunct to diet and exercise in adult patients inadequately 
controlled on their maximal tolerated dose of metformin and a sulfonylurea. 




Metformin = AMPK activator = inhibition of hepatic glucose output 
Route of administration Oral 
Chemical structure Linagliptin 
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EXPERT OPINION  
 All diabetes guidelines recommend metformin, if not contraindicated and if well tolerated, as the 
preferred and most cost-effective first pharmacological agent for the management of type 2 diabetes 
(T2DM). If monotherapy does not achieve/maintain glycated hemoglobin (HbA1c) target, adjusted to 
patient’s  individual pattern, the next step would be to add a second glucose-lowering agent. Choice is based 
on patient characteristics and drug properties, with the overriding goal of improving glycemic control while 
minimising side effects. In this regard, the addition of a dipeptidyl peptidase-4 (DPP-4) inhibitor may offer 
potential benefits over classical sulfonylureas in T2DM patients, despite a higher cost. A lower risk of 
hypoglycemia and weight gain is already well demonstrated with a gliptin as compared to a sulfonylurea, 
despite an almost comparable reduction in HbA1c level. This advantage was confirmed with linagliptin 
compared to glimepiride. The negligible risk of hypoglycemia associated with DPP-4 inhibition is of major 
interest, especially in subjects at higher risk such as elderly people and patients with renal insufficiency. 
Another potential advantage of DPP-4 inhibitors may consist in a better B-cell protection, which 
should result in a longer durability of the glucose-lowering activity. Indeed, sulfonylureas are generally 
associated with a progressive, and sometimes quite rapid, deterioration of glucose control, even when added 
to metformin. This failure requires increased complexity of the glucose-lowering therapy with the 
progression to a strategy including a triple oral treatment or the use of injections (GLP-1 receptor agonists or 
insulin). However, clinical evidence remains scarce in humans and further studies should demonstrate 
whether gliptins really offer a better durability of glucose control compared to sulfonylureas. The recent 2-
year data of a controlled trial comparing linagliptin with glimepiride in patients with T2DM not well 
controlled with metformin monotherapy are insufficient to draw any firm conclusion in this regard. 
A further potential benefit of a DPP-4 inhibitor compared to a sulfonylurea might be a better 
cardiovascular (CV) protection. Indeed, since the University Group Diabetes Program (UGDP) in the 
seventies, the CV safety of sulfonylureas remains questionable. The results of the United Kingdom 
Prospective Diabetes Study (UKPDS) in the late nineties were not completely reassuring with the 
demonstration of an unexplained higher risk in T2DM patients receiving a metformin-sulfonylurea 
combination. In contrast, all available data with DPP-4 inhibitors support the CV safety of this incretin-
based therapy and suggest a CV protection versus placebo or an active comparator. Considering the high CV 
risk commonly associated with T2DM, the fact that gliptins could offer a better CV protection than 
sulfonylureas in patients not well controlled with metformin would be of major interest in clinical practice. 
This hypothesis is currently evaluated in the CAROLINA (“CARdiovascular Outcome study of 
LINAagliptin versus glimepiride in patients with T2DM”) prospective trial comparing linagliptin with 
glimepiride. This is the only prospective trial comparing a DPP-4 inhibitor with an active compound as all 
other ongoing trials are comparing alogliptin, saxagliptin or sitagliptin versus a placebo.    
In the recent ADA-EASD position statement, initial combination drug therapy is limited to patients 
with a high baseline HbA1c (e.g. ≥9.0% [≥75 mmol/mol]) who have a low probability of achieving a near-
normal target with monotherapy. Introducing initial combination therapy (instead of metformin alone) when 
pharmacological treatment is required makes sense considering the complexity of the pathophysiology of 
T2DM, in order to reach therapeutic goal at an earlier stage, have a better stabilisation of this evolving 
disease and avoid or delay subsequent more complex therapies. Because the complementary effects of 
linagliptin and metformin lead to robust and sustained improvements in glycemic control, initial 
combination of the two agents may be considered as a useful treatment option for patients with T2DM as it 
reulst in better glucose control than either monotherapy, with a similar good tolerance profile.  
  By increasing convenience and thereby patient’s adherence, a fixed-dose combination (FDC) may 
offer some advantages in clinical practice. That is the reason why several gliptin plus metformin FDCs are 
now available, the most recently proposed one being Jentadueto® (linagliptin plus metformin). Adherence 
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to therapy is, indeed, a major concern in patients with T2DM who generally share several chronic 
comorbidities and thus should receive multiple medications. However, as the classical formulation of 
metformin hydrochloride should be given twice daily, the linagliptin plus metformin FDC has also to be 
given twice daily while once daily administration of linagliptin is enough to maintain sustained DPP-4 
inhibition over 24 hours. Because metformin should be titrated to improve gastrointestinal tolerance, various 
FDC forms with different strengths of metformin have been developed. If the use of metformin would be 
extended to patients with mild to moderate renal impairment in the future, this may also allow the prudent 
use of such combination, with a reduced metformin dosage, in these circumstances. 
Linagliptin has a unique pharmacokinetic profile compared to other DPP-4 inhibitors, with a very 
low renal excretion. This characteristic allows use linagliptin in T2DM patients with chronic kidney disease 
(from mild to severe) without contra-indication and any dose adjustment. Considering the large number of 
patients with some degree of renal impairment (especially in the elderly population), this may represent an 
advantage over other DPP-4 inhibitors whose daily dose should be adjusted according to the reduction of 
estimated glomerular filtration rate (eGFR). However, the situation of Juntadueto®) is less clear because of 
the presence of metformin. Indeed, renal impairment (eGFR < 60 ml/min) is considered as an official 
contraindication of metformin because of the potential risk of lactic acidosis in case of biguanide 
accumulation. Nevertheless, there is an ongoing debate as to whether these thresholds are too restrictive and 
thereby not allow patients with mild-moderate renal impairment gain more benefit than harm from using 
metformin. In the recent ADA-EASD position statement, it is considered that metformin may be used down 
to a GFR of 30 ml/min, with dose reduction advised below 45 ml/min. If so, the use of linagliptin plus 
metformin, either separately or as FDC, would be extended to a larger population of patients with T2DM 
and the specific advantage of linagliptin regarding its use independent of renal function would even be better 
appreciated in clinical practice. 
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